AI-Driven Coronary Physiology Software Gains FDA Clearance
The software, powered by artificial intelligence and deep learning, assesses angiography-derived coronary physiology in patients with ischemic coronary artery disease.
The software, powered by artificial intelligence and deep learning, assesses angiography-derived coronary physiology in patients with ischemic coronary artery disease.
The FDA determined that the company has submitted copied, falsified, or otherwise invalid data in submissions to the agency.
The FDA warned of a shortage of pediatric medical devices and urged Congress to bolster its ability to track and anticipate these issues.
HeartBeam announced that the FDA has granted 510(k) clearance of the HeartBeam system for comprehensive arrhythmia assessment.
Philips has updated instructions for several ventilators to address aerosol deposits on internal sensors when used with in-line nebulizers.
Admetsys announced that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
The U.S. FDA has proposed banning electrical stimulation devices for self-injurious or aggressive behavior due to significant risks, marking the second attempt at prohibition, with implications including potential treatment transitions for users and a thorough review of updated evidence and expert opinions.